

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

BOX

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Fyperix 402 mg spot-on solution for dogs
Fyperix vet 402 mg spot-on solution for dogs
Fipronil

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

1 pipette (4.02 ml) contains:

Active substance:

Fipronil 402 mg

Excipients:

Butylhydroxyanisole (E320)	0.804 mg
Butylhydroxytoluene (E321)	0.402 mg

3. PHARMACEUTICAL FORM

Spot-on solution

4. PACKAGE SIZE

1 unit-dose pipettes of 4.02 ml
3 unit-dose pipettes of 4.02 ml
6 unit-dose pipettes of 4.02 ml
10 unit-dose pipettes of 4.02 ml
20 unit-dose pipettes of 4.02 ml
30 unit-dose pipettes of 4.02 ml

5. TARGET SPECIES

Dogs (over 40 kg)

6. INDICATION(S)

Treatment of fleas, ticks and lice.


7. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

Spot-on use.

Administer by topical application to the skin according to the bodyweight as follows: 1 pipette of 4.02 ml per dog weighing over 40 kg up to 60 kg bodyweight, and one

pipette of 4.02 ml and an appropriate smaller pipette per dog weighing over 60 kg bodyweight.



8. WITHDRAWAL PERIOD

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.

10. EXPIRY DATE

EXP:

11. SPECIAL STORAGE CONDITIONS

Store in the original container in order to protect from light and moisture. The product should be maintained at room temperature (above 14°C) for approximately one hour prior to administration.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: read package leaflet.
Fipronil may adversely affect aquatic organisms. Do not contaminate ponds, waterways or ditches with the product or empty container.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only.

14. THE WORDS “KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

KRKA, d.d., Novo mesto
Šmarješka cesta 6
8501 Novo mesto
Slovenia

16. MARKETING AUTHORISATION NUMBER

Vm 01656/4040

17. MANUFACTURER'S BATCH NUMBER

Lot:

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

LABEL

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Fyperix 402 mg spot-on solution for dogs
Fyperix vet 402 mg spot-on solution for dogs
Fipronil

2. QUANTITY OF THE ACTIVE SUBSTANCE(S)

Fipronil 402 mg

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

1 unit-dose pipette of 4.02 ml

4. ROUTE(S) OF ADMINISTRATION

Spot-on use.
Dogs (over 40 kg)



5. WITHDRAWAL PERIOD

6. BATCH NUMBER

Lot

7. EXPIRY DATE

EXP

8. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

PIPETTE

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Fyperix 402 mg
Fyperix vet 402 mg
Fipronil

2. QUANTITY OF THE ACTIVE SUBSTANCE(S)

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

4.02 ml

4. ROUTE(S) OF ADMINISTRATION

5. WITHDRAWAL PERIOD

6. BATCH NUMBER

Lot

7. EXPIRY DATE

EXP

8. THE WORDS "FOR ANIMAL TREATMENT ONLY"

PACKAGE LEAFLET FOR:

Fyperix 67/134/268/402 mg spot-on solution for dogs
Fyperix vet 67/134/268/402 mg spot-on solution for dogs

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
AND OF THE MANUFACTURING AUTHORISATION HOLDER
RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder and manufacturer responsible for batch release:

KRKA, d.d., Novo mesto
Šmarješka cesta 6
8501 Novo mesto
Slovenia

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Fyperix 67/134/268/402 mg spot-on solution for dogs
Fyperix vet 67/134/268/402 mg spot-on solution for dogs

Fyperix 67/134/268/402 mg spot-on solution for dogs (United Kingdom, France,
Germany, Portugal, Spain, Netherlands, Italy)

Fyperix vet 67/134/268/402 mg spot-on solution for dogs (Denmark, Finland,
Sweden, Norway)

Fipronil

**3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER
INGREDIENT(S)**

Each unit dose (pipette) contains:

Unit dose	Active substance	Strength	Excipient Butylhydroxyanisole (E320)	Excipient Butylhydroxytoluene (E321)
Fyperix 67 mg	Fipronil	67 mg	0.134 mg	0.067 mg
Fyperix 134 mg	Fipronil	134 mg	0.268 mg	0.134 mg
Fyperix 268 mg	Fipronil	268 mg	0.536 mg	0.268 mg
Fyperix 402 mg	Fipronil	402 mg	0.804 mg	0.402 mg

Light yellow to yellow, clear liquid.

4. INDICATION(S)

Treatment of flea (*Ctenocephalides* spp.) and tick (*Dermacentor reticulatus*) infestations.

For treatment of *Trichodectes canis* biting lice infestations on dogs. Most lice are killed within 2 days.

Insecticidal efficacy against new infestations with adult fleas persists for up to 8 weeks.

The product has a persistent acaricidal efficacy for up to 3 weeks against *Ixodes ricinus* and up to 4 weeks against *Rhipicephalus sanguineus* and *Dermacentor reticulatus*. If ticks of some species (*Ixodes ricinus*, *Rhipicephalus sanguineus*) are present when the product is applied, all the ticks may not be killed within the first 48 hours.

The product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD) where this has been previously diagnosed by a veterinary surgeon.

5. CONTRAINDICATIONS

Do not use on puppies less than 2 months old and/or weighing less than 2 kg in the absence of available data.

Do not use on sick (e.g. systemic diseases, fever...) or convalescent animals.

Do not use in rabbits, as adverse reactions and even death could occur.

This product is specifically developed for dogs. Do not use in cats, as this could lead to overdosing.

Do not use in known cases of hypersensitivity to fipronil, dimethyl sulfoxide or to any of the excipients.

6. ADVERSE REACTIONS

If licking occurs, a brief period of hypersalivation may be observed.

Among the extremely rare suspected adverse reactions, transient cutaneous reactions on the application site (skin discoloration, local alopecia, pruritus, erythema) and general pruritus or alopecia have been reported after use.

Exceptionally, hypersalivation, reversible neurologic symptoms (hyperesthesia, depression, nervous symptoms), vomiting or respiratory symptoms have been observed after use.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports).

If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon.

7. TARGET SPECIES

Dogs

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Route of administration and dosage:


External use only.

Administer by topical application to the skin according to the bodyweight as follows:

Dogs	Number of pipettes	Pipette volume	Potency
over 2 kg and up to 10 kg	1 pipette	0.67 ml	67 mg
over 10 kg and up to 20 kg	1 pipette	1.34 ml	134 mg
over 20 kg and up to 40 kg	1 pipette	2.68 ml	268 mg
40 kg and up to 60 kg	1 pipette	4.02 ml	402 mg
over 60 kg	1 pipette + appropriate smaller pipette	4.02 ml + appropriate combination	402 mg + appropriate combination

Method of administration:

1. Remove the pipette from the triplex bag. Hold the pipette in an upright position, twist and pull the cap off.
2. Turn the cap around and place the other end of the cap back on the pipette. Push and twist the cap to break the seal, then remove the cap from the pipette.
3. Spread the animal hairs in the area between the shoulder blades to make the skin visible.
4. Put the tip of the pipette onto the skin and press the unit-dose pipette several times to empty its contents directly onto the skin at one or two spots.



9. ADVICE ON CORRECT ADMINISTRATION

It is important to make sure that the product is applied to an area where the animal cannot lick it off, and to make sure that animals do not lick each other following treatment.

The hair should be parted and the product applied to the skin. Temporary changes to the coat (clumped/greasy hair and/or deposits on the hair) may be noted at the application site.

For optimal control of flea and/or tick infestation the treatment schedule can be based on the local epidemiological situation.

In the absence of safety studies, the minimum treatment interval is 4 weeks.

10. WITHDRAWAL PERIOD

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Store in the original container in order to protect from light and moisture.

The product should be maintained at room temperature (above 14°C) for approximately one hour prior to administration.

Do not use this veterinary medicinal product after the expiry date which is stated on packaging after EXP. The expiry date refers to the last day of that month.

12. SPECIAL WARNING(S)

Special warnings for each target species

Bathing/immersion in water within two days after application of the product should be avoided. After weekly immersions in water for one minute the period of persistent insecticidal efficacy against fleas was 7 weeks.

The product does not prevent ticks from attaching to the animals. If the animal has been treated prior to exposure to the ticks, the ticks will be killed in the first 24-48 hours after attachment. This will usually be prior to engorgement, minimising but not excluding the risk of transmission of diseases. Once dead, ticks will often drop off the animal, but any remaining ticks may be removed with a gentle pull.

Fleas from pets often infest the animal's basket, bedding and regular resting areas such as carpets and soft furnishings which should be treated, in case of massive infestation and at the beginning of the control measures, with a suitable insecticide and vacuumed regularly.

When used as part of a strategy for the treatment of Flea Allergy Dermatitis, monthly applications to the allergic patient and to other dogs and cats in the household are recommended.

For optimal control of flea infestation in multi-pet household, all dogs and cats in the household should be treated with a suitable insecticide.

Animals should be weighed accurately prior to treatment.

Avoid contact with the animal's eyes. In the case of accidental eye contact, immediately and thoroughly flush the eyes with water.

It is important to make sure that the product is applied to an area where the animal cannot lick it off and to make sure that animals do not lick each other following treatment.

Do not apply the product on wounds or damaged skin.

Laboratory studies using fipronil have not shown any evidence of teratogenic or embryotoxic effect. Studies have not been carried out with this product in pregnant and lactating bitches. Use in pregnancy and lactation only in accordance with professional veterinary advice and a benefit/risk assessment.

No adverse effects were observed in target animal safety studies in 8 week-old puppies, growing dogs and dogs weighing about 2 kg treated once at five times the recommended dose. The risk of experiencing adverse effects (see section 6) may however increase when overdosing, so animals should always be treated with the correct pipette size according to bodyweight.

Fipronil may adversely affect aquatic organisms. Dogs should not be allowed to swim in water courses for 2 days after application.

User warnings

This product can cause mucous membrane and eye irritation. Therefore, contact between the product and the mouth or eyes should be avoided.

In the case of accidental eye contact, immediately and thoroughly flush the eyes with water. If eye irritation persists seek medical advice and show the package leaflet or the label to the physician.

Do not smoke, drink or eat during application.

Avoid contents coming into contact with the fingers. If this occurs, wash off immediately with soap and water.

Wash hands after use.

People with a known hypersensitivity to fipronil or dimethyl sulphoxide or other excipients should avoid contact with the veterinary medicinal product.

Treated animals should not be handled until the application site is dry, and children should not be allowed to play with treated animals until the application site is dry. It is therefore recommended that animals are not treated during the day, but should be treated during the early evening, and that recently treated animals should not be allowed to sleep with owners, especially children.

Keep pipettes in original packaging and dispose of used pipettes immediately.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Fipronil may adversely affect aquatic organisms. Do not contaminate ponds, waterways or ditches with the product or empty container.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

15. OTHER INFORMATION

White polypropylene pipette closed with either a polyethylene or polyoxymethylene cap. Each pipette is packed in a polyethylene terephthalate/aluminium/low density polyethylene triplex bag.

Box containing 1, 3, 6, 10, 20 or 30 pipettes.

Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

Approved: 03 May 2017

